RGNT (Regentis Biomaterials) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 09, 2026)


RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $3.58
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials 5-Year Yield-on-Cost %?

Regentis Biomaterials RGNT -1.65% 14 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Regentis Biomaterials ranks worse than 305810.09% on this metric.

Regentis Biomaterials's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Regentis Biomaterials's 5-Year Yield-on-Cost % or its related term are showing as below:



RGNT's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.39
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Regentis Biomaterials  (AMEX:RGNT) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Regentis Biomaterials 5-Year Yield-on-Cost % Related Terms

RGNT vs HBIO, MLSS, RVP: 5-Year Yield-on-Cost % Comparison

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regentis Biomaterials 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's 5-Year Yield-on-Cost % falls into.


RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Regentis Biomaterials is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Regentis Biomaterials (RGNT) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Regentis Biomaterials and its competitors. According to the industry distribution chart, Regentis Biomaterials ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Regentis Biomaterials' 5-Year Yield-on-Cost % too high?
Regentis Biomaterials' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Regentis Biomaterials ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' 5-Year Yield-on-Cost % compare to HBIO and MLSS?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places Regentis Biomaterials in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.39, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Regentis Biomaterials and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.58
Price